research No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
Search
for
Sort by
Research
30 / 1000+ results
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
research Low-dose oral minoxidil for androgenetic alopecia is not associated with blood pressure changes in patients also taking other antihypertensive medications: A multi-center cohort study using TriNetX
Low-dose oral minoxidil doesn't affect blood pressure in patients taking blood pressure meds.
research The Association Between 5α-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study
Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
research Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study
research Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
research Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
research Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
research Broad laboratory testing does not show utility for telogen effluvium: a retrospective analysis of 22-million laboratory results using TriNetX
research Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
research Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.
research The Risk of Benign Prostatic Hyperplasia and Prostate Cancer With Long-Term, Low Dose Finasteride Use in Adult Men with Nonscarring Alopecia: A Propensity-Matched Observational Study
Long-term, low-dose finasteride may reduce the risk of benign prostatic hyperplasia and prostate cancer.
research 0250 Systemic therapy associates with a lower incidence of male infertility among psoriasis patients
Systemic therapy may reduce male infertility in psoriasis patients.
research 53028 Semaglutide and Hair Loss: A Real-World Analysis
Semaglutide does not significantly increase the risk of hair loss.
research LB892 Assessing the risk of alopecia areata development in patients with seasonal and food allergies: a matched population-level analysis
Allergies, especially both seasonal and food, increase the risk of developing alopecia areata.
research 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study
Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
research Low serum testosterone is associated with an increased risk of first-time renal calculi in men without testosterone replacement therapy
Low testosterone increases kidney stone risk in men not on testosterone therapy.
research Association of Janus kinase inhibitors with reduced depression in alopecia areata
JAK inhibitors may reduce depression in people with alopecia areata.
research Association Between Urolithiasis and Hidradenitis Suppurativa: A Retrospective Cohort Study
People with hidradenitis suppurativa have a higher risk of kidney stones.
research Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
GLP-1RA therapy may increase the risk of hair loss.
research Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors
Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
research Finding Long-COVID: temporal topic modeling of electronic health records from the N3C and RECOVER programs
Long-COVID causes more health issues after COVID-19, varying by age, sex, and infection wave.
research Repositioning Old Drugs for New Battles: The Expanding Role of Drug Repurposing in Cancer, Inflammation, and Metabolic Disease.
Drug repurposing can create safer, cheaper treatments by finding new uses for existing drugs.
research Menopause and Common Dermatoses: A Systematic Review
Menopause influences skin conditions, and hormone therapy should be considered in treatment.
research Semaglutide and the Skin: An Overview of Current Evidence
Semaglutide may help some skin disorders but can also cause skin issues.
research Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review
GLP-1 agonists may help treat certain skin conditions.
research Finding Long-COVID: Temporal Topic Modeling of Electronic Health Records from the N3C and RECOVER Programs
Long-COVID has diverse, long-term health impacts, especially in young people.
research Monilethrix: the use of tricoscopy in clinical diagnosis
Monilethrix is a genetic disorder causing brittle hair, diagnosed using tricoscopy.